Trial · NCT02302833
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
NCT02302833, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2025-07-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery. Trials, record NCT02302833. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02302833
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
- NCT number
- NCT02302833
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 21 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Regional Adrenal Gland Pheochromocytoma, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
- Interventions
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Questionnaire Administration
- First posted
- 2014-11-27
- Last updated
- 2025-07-31
- Results first posted
- 2025-07-31
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate | 6 months |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response Rate | 6 months | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate | Cabozantinib | 25 | 95% Confidence Interval 7.3 to 52 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cabozantinib | 20 | |
| Overall Study | COMPLETED | Cabozantinib | 17 | |
| Overall Study | NOT COMPLETED | Cabozantinib | 3 |
Source ClinicalTrials.gov
Adverse events197
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | Cabozantinib | 3 | 20 | |
| other | Abdominal pain | Gastrointestinal disorders | Cabozantinib | 8 | 20 | |
| other | Activated partial thromboplastin time prolonged | Blood and lymphatic system disorders | Cabozantinib | 7 | 20 | |
| other | Agitation | General disorders | Cabozantinib | 1 | 20 | |
| other | Alanine aminotransferase increased | Investigations | Cabozantinib | 15 | 20 | |
| other | Alkaline phosphatase increased | Investigations | Cabozantinib | 11 | 20 | |
| other | Allergic rhinitis | General disorders | Cabozantinib | 1 | 20 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Cabozantinib | 8 | 20 | |
| other | ALT increased | Investigations | Cabozantinib | 1 | 20 | |
| other | Anal fistula | General disorders | Cabozantinib | 1 | 20 |
1 to 10 of 197Source ClinicalTrials.gov
See all 197 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cabozantinib | 0 | 20 |
| Total, other adverse events | Cabozantinib | 20 | 20 |
| Total, serious adverse events | Cabozantinib | 20 | 20 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38608693 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA016672 | The University of Texas MD Anderson Cancer Center Support Grant (CCSG) | KOONG, ALBERT | UNIVERSITY OF TX MD ANDERSON CAN CTR | NATIONAL CANCER INSTITUTE | 1985 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02302833
GET https://conductscience.org/api/trials/v1/NCT02302833/events?page=2